CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Core Points - CytoDyn Inc. is a clinical-stage biotechnology company focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications [1][2] - The company announced a change in the timing of its management's live presentation at the H.C. Wainwright 27th Annual Global Investment Conference to September 10, 2025, at 9 a.m. EDT [1][2] - CytoDyn's mission is to improve patients' quality of life through therapeutic innovation, emphasizing integrity, responsibility, and service [3] Event Details - The H.C. Wainwright 27th Annual Global Investment Conference will take place from September 8-10, 2025, in New York City [2] - CFO Robert E. Hoffman will deliver a live presentation and be available for one-on-one meetings during the event [2] Company Information - CytoDyn is dedicated to bringing transformative treatments to patients worldwide, particularly focusing on immune function related to cancer, infectious diseases, and autoimmune disorders [2][3] - For more information, the company can be contacted through its investor relations email or its media contacts [4]